Our study comprises a cases series of 71 men attending a dermatology clinic in Brazil during an 18-month period with anogenital HPV infection. Clinical manifestations, laboratory findings and sociodemographic factors were evaluated. Biopsy samples were subjected to histopathological analysis, generic and type-specific viral identification, and p16 INK4a quantification. The average age at diagnosis was 33 years. We observed little variation in identified viral types (HPVs 6, 11, 16 and 53), despite the inclusion of 16 HIV+ patients. The presence of high-risk HPV was associated with receptive anal sex (p<0.05), lesion malignancy (p<0.01) and p16
INTRODUCTION
Human papillomavirus (HPV) infection causes one of the most prevalent sexually transmitted diseases (STDs) worldwide as well as half a million cases of cervical cancer per year, with approximately half of these being fatal (incidence rates of 14.0 per 100,000 women) (HPVcentre, 2014) . The pathological and epidemiological features of HPV infection have been studied extensively in women due to the prevalence of this disease and its well-established link to cervical cancer (CC) (WHO 2012) .
The spectrum of HPV is broad and distributed among viral species that share pathogenic and biological properties. Human genital tract harbors approximately 40 HPV, included in the Alphapapillomaviridae genera. Some types are considered oncogenic due to their association with high grade cervical lesions (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) , while others types are found in benign lesions (6, 11, 13, 42, 43, 44, 54, 55, 61, 72, 81, 84) , some were recently redefined as probably high risk types (26, 53, 66, 68, 73, 82) and others are of undetermined risk (30, 32, 34, 62, 67, 69, 71, 74, 83, 84, cand 85, 86, 87, 90, 91) due to poor epidemiological confirmation (Bernard et al 2010) .
However, HPV infection is also an important concern in men due to the risk of transmission to women and the disease burden. As widely known, anogenital HPV in men may cause anogenital warts (AGWs), which, although benign, may constitute a psychosocial stigma leading to depression and compromised quality of life. The AGW recurrence rate is ~50%, generating multiple visits to health services, requiring different treatments, imposing a high social cost (Palefsky 2010) . It has also recently been associated with several cancers that affect men, including 96% of anal cancers, 40% of oral, and nearly 60% of penile cancers (HPVcentre, 2014) .
Penile cancer is relatively rare worldwide, with higher incidence in some developing countries. Few studies have stated HPV involvement in penile carcinoma. Specific HPV genotypes, predominantly HR-HPVs 16 and 18, have been identified in 40-70% of malignant penile lesions (Afonso et al. 2012) . Nevertheless, HR-HPV has been identified as the etiological agent of 90-96% of anal carcinomas, and persistent infection is a major independent risk factor. HPV 16 has been identified in 65-75% of anal carcinoma specimens, followed by HPV 18 (Abbas et al. 2010) .
The incidence of HPV-related anal cancers is increasing in the general population, reaching 1.0 per 100,000 inhabitants per year and is growing even faster among men who have sex with men (MSM) with human immunodeficiency virus (HIV) infection (Kreuter et al. 2008 , HPVcentre, 2014 . Recently reported data suggest that HPV infection may increase the risk of HIV infection in men. Thus, anogenital HPV infection and related pathologies in men are associated with intangible economic losses and issues extending far beyond HPV transmission to women (Garland 2010) . In this study, we report our experience with men with HPV-induced anogenital lesions attending a general dermatology clinic and describe the clinical, pathological, and virological aspects of this disease.
MATERIAL AND METHODS

Study design and participants
This cross-sectional study evaluated HPV infection in men with anogenital lesions attending the dermatology clinic of Santa Casa de Misericórdia do Rio de Janeiro between January 2011 and July 2012. Clinical sample size calculation (with 95% confidence interval) determined that ≥50 cases were required for this study. To calculate sample size, the number of anogenital lesions in male anogenital tract per year were used (Fedrizzi, 2011) , adapted to Rio de Janeiro State population (1-2% in 10,000,000 male inhabitants).
All participants had clinical indications for biopsy, based on the presence of anogenital lesions with clinical features of HPV infection and one or more of the following features: HIV seropositivity, perianal localization, multicolored pigmentation, erosion, friability, ulceration, erythema, or recurrence despite several therapeutic approaches. Exclusion criteria were age < 18 years and absence of anogenital lesions histopathologically compatible with HPV.
HIV serology and CD4 levels were obtained by patient prontuary, and follows Health Ministery protocols for HIV diagnosis, treatment and follow up (http://www. aids.gov.br/pagina/recomendacoes-de-tratamentoconsensos).
The ethics committee of Fundação Oswaldo Cruz approved this study (CEP IOC 567/2010 ) and all subjects provided written informed consent. Sociodemographic information (education, sexual behavior, circumcision, tobacco and alcohol use, STD history) was collected from all participants by questionnaire.
Sampling
Biopsy samples were collected from anogenital lesions and kept in TE solution [10 mM Tris hydrochloride (pH 7.5), 1 mM ethylenediaminetetraacetic acid (EDTA)] (Invitrogen, USA) at -20°C until DNA extraction.
Histopathological analysis
Paraffin-embedded tissues were processed at the Anatomicallab in Rio de Janeiro, Brazil. Histopathological diagnosis were made using the Bethesda system (WHO, 2012) .
DNA extraction and analysis
Samples were incubated for 4 h at 56°C in 1mL digestion buffer [10 mM Tris hydrochloric acid (pH 8.3), 1 mM EDTA (pH 8.0), 0.5% Tween 20, 400 µg/ml proteinase K (Invitrogen, USA)], then extracted with phenol:chloroform:isoamyl alcohol (25:24:1) (Invitrogen, USA). DNA was precipitated with 300µL 0.3 M sodium acetate plus 900µL of ice-cold ethanol, washed with 70% ethanol, air dried, and suspended in 50 µl sterile water (Afonso et al, 2012) .
MY09/11 consensual primers for HPV detection, which amplify 450-bp DNA sequences in the L1 region, were used to detect generic HPV DNA via polymerase chain reaction (PCR). Thirty-five amplification cycles were carried out in 50 µl reaction mixture (1 X PCR buffer, 200 mM deoxyribonucleoside triphosphates, 1.5 mM MgCl 2 , 50 pmol each primer, 0.25 U Taq polymerase, 5 µl sample) using a DNA thermal cycler (Life Technologies, USA). Each cycle comprised denaturation at 94°C for 1 min, annealing at 55°C for 2 min, and chain elongation at 72°C for 2 min. The beta-actin primers Ac1 and Ac2 (0.1 pmol each), which amplify a 330-bp region of human DNA, were used as internal sample controls (Afonso et al. 2012) .. Specific genotyping was performed by PCR amplification with primers from the E6 gene DNA sequences of Low risk HPVs 6, 11and 53, and High risk HPVs 16, 18, 31, 33, 35, 45, 56, and 58 7 Thirty-five amplification cycles were carried out in 50 µl reaction mixture with denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and chain elongation at 72°C for 1 min (Afonso et al. 2012) ..
For generic and specific genotyping, negative controls for background contamination were added to DNA templates. PCR products were analyzed on 1.3% agarose gel with ethidium bromide staining to visualize DNA under ultraviolet light, and their molecular weights were determined by comparison with a 100-bp DNA ladder.
Restriction fragment length polymorphism (RFLP) analysis for HPV genotyping RFLP was performed following PCR amplification using the 450-bp amplicons resulting from the MY09/11 PCR. Samples untyped by the type specific-PCR were submitted to digestion by a panel of six restriction endonucleases (BamHI, DdeI, HaeIII, HinfI, PstI, RsaI) (Invitrogen, Brazil). The pattern of length polymorphism of each sample was analysed under UV light and compared with RFLP patterns for mucosal virus types, as described by Afonso et al. (2012) .
Immunohistochemical analysis
Five-micron sections were cut onto silanecoated slides (Sigma Chemical Co., St. Louis, MO, USA) and processed for immunohistochemical analysis as described previously (Nicol et al. 2012 ). We used mouse monoclonal primary antibodies against p16INK4a (p16; CINtec cytology kit; MTM Laboratories -Heidelberg, Germany). Briefly, slides were deparaffinized and sections were treated with target antigen retrieval solution (S1699, pH 6.0; DAKO, Copenhagen, Denmark). Primary antibody (100 μl) was applied in a humidified chamber at 4°C overnight. The labeled streptavidin biotin horseradish peroxidase (HRP) system (DakoCytomation, Carpinteria, CA, USA) was adapted for immunolabelling with the universal biotinylated link antibody, and slides were incubated with streptavidin-HRP conjugate for 30 min. Slides were washed three times in Tris (pH 7.6) between incubation steps. Antibody binding was visualized with 3,3'-diaminobenzidine (Sigma Chemical Co.) and 85 µl 0.3% hydrogen peroxide. Finally, slides were counterstained with hematoxylin, dehydrated, and mounted in a resinous medium (Merck, Darmstadt, Germany). Negative controls were generated for all tissues by omitting the primary antibody. Two investigators independently analyzed the slides at ×400 magnification. Digital photographs were taken (Coolpix DP12; Nikon -Tokyo, Japan) and stored using the Image Pro-plus software, Mediacybernetics -Rockville, MD. Cervical epithelial cells (≥200 nuclei) were counted manually and percentages of positively stained cells in representative fields were quantified. p16 positivity was defined as the presence of dark-brown staining in nuclei and/or cytoplasmic compartments (Nicol et al. 2012 ).
Statistical analysis
A database was generated and analyzed using SSPS software (ver. 15; SPSS Inc., Chicago, IL, USA). Biological data were compared using Fisher's exact test (p < 0.05). Risk factors, HPV genotypes, p16 expression, and clinical features were evaluated. Associations of low-risk (LR) and high-risk (HR) HPV infections with sociodemographic variables were examined.
RESULTS
The study sample comprised 71 men [55 HIV seronegative (-), 16 HIV seropositive (+)] with a mean age of 33 ± 11 (range, 18-64) years at diagnosis, with no difference according to HIV status. Patients with HIV were receiving highly active antiretroviral therapy; CD4 count was >265 cells/mm 3 in 15 patients and <50 cells/ mm³ in one patient. All samples exhibited generic HPV DNA positivity and 80.3% (57/71) were genotyped. Of these samples, 86% (49/57) contained one or more LR-HPV genotypes, most frequently HPV 6 (57.9%, 33/57), followed by HPV 11 (40.4%, 23/57).LR-HPV 53 was found in co-infecting with HPV6 a HIV(+) patient. HPV 16 was the only HR-HPV genotype identified; it was present in 14% (8/57) of positive samples. Multiple infections were detected in 14% (8/57) of samples, revealing 5 mixed infections by HPV 6/11, 2 HPV 6/16 and 1HPV6/53 (Table 1) . HPV 16 was significantly related to high-grade lesions (1 AIN II, 3 AIN III) in 50% of affected patients, whereas 98% of low-grade lesions were related to LR-HPV (p < 0.01; Table 2 ). One HIV+ MSM infected with LR-HPV (HPV 11) presented with grade III anal intraepithelial neoplasia (AIN III), which rapidly progressed to invasive anal squamous cell carcinoma (SCC). The analysis of possible correlations between sociodemographic factors and presence of low-and high-risk HPV types showed that passive anal sex was the only variable significantly related to HR-HPV (HPV 16) infection (p < 0.05; Table 3 ).
Regarding the co-infection HPV/HIV, we observed that HIV+ patients showed significant vulnerability to HR-HPV (26,7%, 4/15 vs. 9.5%, 4/42 HIV-patients; p < 0.05; -positive patients were low grade and all high-grade lesions analyzed were p16
INK4a negative (Table 6 ). 
DISCUSSION
In addition to being vectors of anogenital HPV infection, men have recently been recognized to suffer the pathological consequences of this disease, mainly through the clinical manifestations of AGWs and its consequences, AIN, penile intraepithelial neoplasia (PIN), and invasive carcinoma (Palefsky 2010 , Garland 2010 .
Although studies of HPV prevalence in male anogenital lesions have yielded highly variable results, we found that affected men at diagnosis had a mean age of 33 years and observed no significant difference according to be HIV infected or not, in agreement with other studies (Nytray et al. 2009 ). Sampling and methodological strategies used in prevalence studies may also have resulted in diagnostic losses due to the characteristics of HPV infection sites in men and the lack of routine preventive screening to detect anal lesions in at-risk men, whereas such screening is implemented for women (Palefsky et al. 2011) . The difficulty of measuring latent HPV infection reactivation must also be considered (Gravitt 2011) .
We observed low variability in detected HPV genotypes (predominantly HPVs 6 and 11 and only one HPV53), despite the inclusion of HIV+ patients (Table  1) . Kreuter et al. (2008) , using a PCR GP5 + /6 + -EIA found a high prevalence of HPV 16 (in 70% of patients with PIN and 73% with AIN) in an HIV+ population, but also detected HPVs 18, 31, 33, 45, 6, 11, 81, and 83 . Multiple infection was also more common in their population (80%) than in our sample (14%). In agreement with our results, other studies have found low genotypic variation and no difference between HIV+ and HIV-populations (Jamieson et al. 2002) .
Nearly 18.6% of the studied samples remained untyped. The application of both type-specific PCR and RFLP would detect the 49 mucosal types infecting the genital tract. Nevertheless, in male genital tract, HPV types related to skin lesions have already been identified, due to the keratinization of this site (Garland, 2010) . It is important to notice that HPV typing may be hampered because of losses in molecular detection due to sampling, DNA degradation and primer choice. Melgaço et al (2010) using PCR and RFLP, also related that 12.1% of the investigated samples remained untyped, mostly due to complex patterns generated by the polymorphism analysis.
Recent publications have provided considerable evidence of the oncogenic potential of some HR-HPV types in the male anogenital tract (Palefsky 2010 , Hoots et al. 2009 ). In our study, we described that HR-HPV were present in 80% (4/5) of high-grade lesions in only 7.7% (4/52) of LSIL patients, corroborating HR-HPV role in progression to malignization (Table 2) .
Passive anal sex was related to the prevalence of HR-HPV (HPV 16) in this study (Table 3) . Bower et al. (2004) described pronounced HPV 16 tropism in the anal-rectal transformation zone. HPV 16 prevalence can reach 96% in risk groups such as MSM and HIV+ men. However, progression rates have not been extensively studied (Garland, 2010 , Darragh & Winkler, 2011 , Palefsky et al., 2011 .
HR-HPV and perianal lesions were significantly more frequent in HIV+ than in HIV-patients in our sample, consistent with the findings of several recent studies (Tables 4 and 5 ). The prevalence of HPV anogenital infection in HIV+ MSM is 96%, regardless of CD4 count (Palefsky 2010,) . Sobhani et al. (2004) showed that HIV+ was an independent risk factor for anal carcinoma and HR-HPV (especially HPV 16) prevalence. The prevalence of MSM in HIV+ populations in developed countries and the frequency of anal HPV infection in these populations must also be considered (Palefsky 2010) . In our study, 60% of MSM were HIV+.
It's a relevant finding since the risk of AIN is high among HIV+ and immunocompromised individuals, MSM, and women with histories of cervical/vulvar cancer (Darragh & Winkler, 2011) . Individuals with AIDS are also at increased risk of developing invasive anal carcinoma, the incidence of which has increased significantly in this group in recent years (Kreuter et al. 2008 , Palefsky et al. 2011 . The risk of penile carcinoma is also higher in HIV+ than in HIV-men, but it is much rarer than anal carcinoma. In a recent metaanalysis, Grulich et al.(2007) reported incidence rates of 4.42/100,000 for penile carcinoma and 28.75/100,000 for anal carcinoma in patients with HIV/AIDS.
We found that high-grade lesions were more frequent and diagnosed at a significantly younger age in HIV+ than in HIV-patients. Thus, HPV infection clearly manifests earlier and is more severe in HIV+ patients than in the general population. The incidence rate of anal carcinoma in the general population is higher in women than in men aged > 50 years, but lower in women than in men aged 20-49 years, reflecting an increased incidence among HIV+ MSM in the latter age group (Abbas et al. 2010) . Kreuter et al. (2008) recognized that the risk factors for anal carcinoma included a history of AGWs, numerous sexual partners, persistent HPV 16 or 18 infection, and CD4 count < 500 cells/mm³. All HIV+ patients in our sample had CD4 counts < 500 at the time of diagnosis, and HPV 16 was identified in three of these patients. LR-HPV (HPV 11) was detected in one HIV+ patient with anal SCC; a meta-analysis (Hoots et al. 2009 ) also described HPV 11 detection in anal carcinoma, reflecting the opportunistic malignant behavior of this otherwise benign genotype. Gormley and Kovarik (2009) suggested that HIV+ patients could maintain more HPV latent infections and that reactivation could occur more frequently, increasing the risks for all types of intraepithelial neoplasias and carcinoma.
Anal cancer incidence rates have increased in some groups, such as MSM and HIV+ men. A study conducted in San Diego-California (Fox 2009) , revealed an annual incidence in this group of 224/100,000, which is higher than those for CC before the introduction of routine Papanicolaou testing. This increase comes at a time when diagnostic and therapeutic protocols and vaccination recommendations for boys, are lacking in most countries (Palefsky 2010) . Papanicolaou cytological screening has been proposed, but no consensus regarding sensitivity and specificity rates has been reached (Fox 2009 ). Histopathological studies are considered a good option, although subclinical lesions can be detected only with high-resolution videocolposcopy (Palefsky et al. 2011 , Gormley & Kovarik, 2009 . Few specialties, than gynecologists, have been trained in the application of this technology, and diagnostic losses also can occur due to the obscuring of intraepithelial lesions by perianal and anal warts (Fox 2009 ).
Viral nucleic acid detection is highly sensitive and specific. PCR and hybrid capture are valuable screening tools for at-risk patients, but they are expensive and unavailable in most health services. Moreover, practical significance of the results requires knowledge about viral behavior and the examined pathology. Hence, several groups have examined the use of biomarkers for prognostic evaluation of HPV lesion progression to malignancy. The tumor suppressor protein p16INK4a has been intensively studied, but results have been controversial. We detected p16INK4a expression in 32% of specimens, all low-grade lesions, contradicting the proposed use of p16INK4a to evaluate the risk of malignant progression. It is relevant to notice that only a small number of HSIL were studied. However, we observed a significant association between p16INK4a positivity and HPV 16 presence, indicating that p16INK4a may serve as a complementary biomarker for HR-HPV. Although we analyzed a small, discrete sample, our results agree with many authors (Gormley & Kovarik 2009). Cubilla et al. (2011) demonstrated that HR-HPVs were correlated with p16INK4a positivity in ~80% of penile carcinoma cases, and suggested that p16INK4a negativity could indicate the HPV DNA absence or monoviral LR-HPV infection. Gupta et al. (2010) showed higher p16INK4a expression in cervical HR-HPV lesions and a weak staining pattern in LR-HPV lesions, consistent with our data (Table 6 ). In this systematic review, meta-analysis and trails pointed out the difficulty of evaluating the use of p16INK4a immunohistochemistry for cytological and histological samples due to the lack of a standardized methodology. Quadrivalent HPV vaccine is highly efficacious for the prevention of AGWs and precancerous cervical, vulvar, and vaginal lesions, prompting efforts to define its role in the prevention of male genital disease (Palefsky 2010) . Although the protective efficacy of HPV vaccination in men has not been fully established, pending the outcomes of public policy discussions and cost-efficacy studies, a strong rationale may underlie the vaccination of boys, like girls, at an early age, when they have engaged in limited or no sexual activity. Recent interim data have shown that this vaccine is highly effective in reducing external genital lesions in young men (Palefsky et al. 2011) . In this study, all HPV genotypes detected are present in the quadrivalent vaccine.
For these reasons, we believe that experience and appropriate clinical examination remain the best tools for early diagnosis of malignant disease. We noted that patients, physicians in HIV clinics, and specialists attending MSM rarely conducted anogenital (self-) inspection or digital anal (self-)examination. However, we believe that a crucial difference between this early diagnosis and that of CC is the index of clinical suspicion, i.e., understanding the importance of screening. The need for cervical cytological screening in women is widely recognized in the medical community and the public, but the risk of anal carcinoma has not received such recognition (Darragh & Winkler, 2011) . We observed that few men, especially HIV+ MSM, knew that they were at risk of developing anal carcinoma. In agreement with Fox (2009) our experience indicates that the education of men (like women) in self-examination and risk factors, and the awareness of healthcare staff regarding the need for prevention, are effective and low-cost measures to prevent HPV lesion progression to invasive anal SCC. Furthermore, HPV infection is not frequently included in differential diagnoses, reflecting the need for clarification and clinical education.
